Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
Holding CBUS?
Track your performance easily
CBUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.37 - $23.18
Previous Close$2.65
Volume526.97K
Average Volume (3M)167.95K
Market Cap
$82.79M
Enterprise Value$103.47M
Total Cash (Recent Filing)$28.80M
Total Debt (Recent Filing)$36.74M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Mar 20, 2025EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.48
Shares Outstanding29,568,098
10 Day Avg. Volume303,054
30 Day Avg. Volume167,954
Standard Deviation0.41
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.72
Price to Sales (P/S)19.94
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.91
Enterprise Value/Gross Profit56.94
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$18.13Price Target Upside585.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cibus News
PremiumCompany Announcements
Cibus Enhances Board with Appointment of August Moretti
PremiumCompany Announcements
Cibus Reports Strategic Shift and Financial Update
PremiumCompany Announcements
Cibus Advances in Agricultural Biotechnology InnovationsBulls Say, Bears Say
Bulls Say
Financial PerformanceCibus reported Q3/24 revenues of $1.7M, which beat consensus by ~143%, driven by collaboration agreements for Soybean contract research.
Market ExpansionThe company plans to get its Soybean platform operational by end of 2024, opening up another large market that could be as large as 125M acres.
Technological AdvantageThe 'transformative' nature of Cibus' trait machine gene editing process offers a significant competitive advantage, with higher conversion ratios compared to other techniques like Crispr.
Bears Say
Analyst RecommendationThe analyst is lowering the price target to $20, indicating a less optimistic outlook for the stock's future performance.
Financial PerformanceCibus reported a net loss of approximately $202 million, primarily due to a significant goodwill impairment charge during the quarter.
RisksMultiple risks such as dilution risk, execution risk, regulatory risk, demand risk, technology risk, and competition risk, along with uncertainty related to macroeconomic conditions and the geopolitical environment, could negatively impact the stock.
---
Ownership Overview
25.84% Insiders
11.99% Mutual Funds
5.28% Other Institutional Investors
51.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $2.37 and its highest was $23.18 in the past 12 months.
What is Cibus’s market cap?
Currently, no data Available
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Mar 20, 2025 which is in 89 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Nov 07, 2024. The company reported -$7.63 earnings per share for the quarter, missing the consensus estimate of -$0.873 by -$6.757.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -$0.74.
How many shares outstanding does Cibus have?
Cibus has 26,455,582 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$7.63 in its last earnings report, missing expectations of -$0.873. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Cibus?
Among the largest hedge funds holding Cibus’s share is Swan Global Investments, Llc. It holds Cibus’s shares valued at 115K.
---
Cibus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.13 (585.44% Upside)
$18.13 (585.44% Upside)
Blogger Sentiment
Bullish
CBUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 35.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.81%
12-Months-Change
Fundamentals
Return on Equity
-155.86%
Trailing 12-Months
Asset Growth
-53.80%
Trailing 12-Months
Company Description
Cibus
Calyxt, Inc. operates as a healthy food ingredient company. It engages in the development of crops by leveraging processes that occur in nature, combining its gene-editing technology and technical expertise with its commercial strategy to bring healthier ingredients to the market. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010 and is headquartered in Roseville, MN.
---
CBUS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed significant progress in Cibus's transformation to a commercial gene editing company, with successful trait developments and strategic collaborations. However, financial challenges persist with increased net losses, and there are ongoing regulatory and commercialization hurdles.Read More>---
CBUS Stock 12 Month Forecast
Average Price Target
$18.13
▲(585.44% Upside)
Technical Analysis
Best Analysts Covering CBUS
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-69.23%
reiterated a buy rating last month
Copying Amit Dayal's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -69.23% per trade.
---